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A primer on cost-effectiveness analyses for vascular
surgeons
Neal R. Barshes, MD, MPH,a James D. Chambers, PhD, MPharm, MSc,b Scott B. Cantor, PhD,c
Joshua Cohen, PhD,b and Michael Belkin, MD,d Houston, Tex; and Boston, Mass
The rate of growth in health care costs in the United States is simply unsustainable. In this economic climate, health care
providers will increasingly be asked to justify the existence of health care programs and management strategies on an
economic basis. An understanding of cost-effectiveness analyses and its components – direct and indirect costs,
quality-adjusted life-years, and incremental cost-effectiveness ratios – is integral to this. We present a primer on the
methodology of cost-effectiveness analyses and a review of published cost-effectiveness analyses of vascular surgery
interventions with the goal of providing the vascular surgeon with a basic understanding of this topic. ( J Vasc Surg 2012;
55:1794-800.)
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sIn today’s global economic climate, health care provid-
ers may increasingly be asked to justify the existence of their
health care programs and management choices on an eco-
nomic basis. Many U.S. health care institutions provide
care that cannot be matched anywhere else in the world,
but the high cost associated with health care in the U.S. is
increasingly compromising our ability to ensure adequate
access to all our citizens and may even be outgrowing our
economy’s ability to pay for such care.1 Patients and payers
are increasingly demanding that health care providers pro-
vide good results while minimizing costs – in other words,
that we optimize the “value” or cost-effectiveness of health
care interventions. Physicians, policy makers, and research-
ers all play a role in such efforts. Just as vascular surgeons
have become leaders in ensuring quality and patient safety,
it is imperative that vascular surgeons also work to optimize
the “value” or cost-effectiveness of care we provide to
patients.1
With this imperative in mind, we review the essential
concepts and basic methodology important to understand-
ing of cost-effectiveness in health care in general, followed
by a review of the cost-effectiveness analyses published to
date on vascular surgery interventions.
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1794MPORTANT CONCEPTS IN
OST-EFFECTIVENESS ANALYSES
The definition and aims of cost-effectiveness
nalyses. Economic analyses in general provide a frame-
ork with which to prioritize the spending of scare re-
ources. In the context of health care, economic analyses
uch as cost-effectiveness analyses help maximize the health
enefits obtained from the resources spent to obtain these
enefits. These analyses may focus on anything considered
health technology, including diagnostic tests, preventa-
ive measures, and treatment strategies.2 Like randomized
linical trials, economic analyses are primarily comparisons
f two or more health technologies. The strategies exam-
ned range from a single test or intervention done at one
oint in time (eg, ultrasound screening to identify moder-
te to severe carotid stenosis) to a combination of tests
nd/or interventions done over a period of time (eg,
epeated endovascular intervention for limb salvage).
The term cost-effectiveness analysis refers to an analysis
hat compares the incremental costs and the incremental
ffectiveness of two or more health technologies.2 Effec-
iveness can be measured using virtually any clinical mea-
ure of health benefit, such as episode-free days, percent
ecrease glomerular filtration rate, or foot ulcer recur-
ences. Most often, contemporary cost-effectiveness analy-
es use quality-adjusted life-years (QALYs) as the measure
f effectiveness, as QALYs incorporate both health utility
the relative preference for a given health state or outcome)
nd patient survival time into a single measure. The subset
f cost-effectiveness analyses that use QALYs or another
easure of utility are sometimes referred to as cost-utility
nalyses.
The numerator: The costs of health care technologies.
s a general term, a cost refers the amount of resources
onsumed for a particular service or given in exchange for a
articular item. The costs considered are typically catego-
ized as direct or indirect costs. Direct costs are the costs of
tems or services that can be linked directly with one con-
umer or patient, such as stent grafts and medication doses.
n contrast, indirect costs are costs that are difficult to link
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Volume 55, Number 6 Barshes et al 1795directly to a patient on a one-to-one basis. Examples of
indirect costs include the capital costs associated with
building and maintaining an operating room and overhead
costs such as the costs for housekeeping, advertising, or
management services. Methods such as transition cost ac-
counting3 and activity-based cost accounting4 have been
developed to equitably assign indirect costs to units of
production. No gold standard accounting method for in-
direct costs has been established, but it is important that
indirect costs be estimated in some fashion and included in
a cost-effectiveness analysis. It also bears mentioning that in
obtaining cost estimates, costs should be distinguished
from charges, as the latter simply represent the monetary
amount billed to the patient or payer and typically have a
very poor correlation with the true cost of care as measured
in terms of resource consumption (see Finkler5).
The perspective of a cost-effectiveness analysis deter-
mines which costs are to be included. The first aspect to
consider is that of the payer: whose costs are going to be
included in the analysis? The least inclusive perspective is
the hospital perspective and includes only the costs in-
curred during an inpatient hospital stay. The payer perspec-
tive includes both inpatient and outpatient costs – in other
words, the costs that might be incurred by the typical
third-party payer. The societal perspective is the most in-
clusive and considers all costs: not only the inpatient and
outpatient costs but all other costs associated with a given
choice, including other costs incurred by the patient (eg,
out-of-pocket costs) and costs to others (eg, the lost work-
days of relatives functioning as caretakers).6 Less-inclusive
perspectives such as the hospital perspective give an incom-
plete picture of the total costs and may engender cost-
shifting, so the societal perspective should generally be
taken in a cost-effectiveness analysis.
The time perspective describes the interval of time that
is to be considered for the accumulation of costs. The
analytical horizon of the study should begin not simply
when the treatment is implemented, but rather when the
decision for the given treatment option is initiated, thereby
including all preintervention diagnostic work and other
preparations. In addition, the costs associated with the
initial treatment and any subsequent “downstream” costs
that result are also included. For example, using prosthetic
conduits in femoropopliteal bypasses done for claudication
generally produces satisfactory results but may rarely lead to
costly complications such as graft infection or thrombosis
with limb-threatening ischemia. Likewise, procedures that
have a low initial cost but are less durable and therefore
require repetition may actually be more costly than a more
durable procedure with a higher initial cost. For the analysis
to be complete, the costs of these downstream effects need to
be included in the analysis. Indeed, most cost-effectiveness
studies use projected lifetime as the time horizon of the
study – that is, the costs and effectiveness from the time
of intervention through the duration of the patient’s life.
The denominator: health utilities and QALYS.
Most often, the denominator in the cost-effectiveness
equation is health utility: the value or preference a patient tas for a given health state.7 Health-related quality of life is
related construct, and instruments used to measure qual-
ty of life can be used that can indirectly measure health
tility. Measuring health utility before and at several time
oints after an intervention using one of several instru-
ents such as the Short Form-6D, the European Quality of
ife-5 Dimensions, the Health Utilities Index Mark 2 or 3,
r the Quality of Well-Being (see review by Thoma and
cKnight8) allows the product of health utility and survival
o be calculated in the form of QALYs. An intervention that
oubles survival time, for example, but is associated with a
0% decrease in health utility (ie, a worse health state) will
ield no additional net QALYs.
As with any quantitative measurement, QALYs are imper-
ect measures of effectiveness, and the idea that QALYs un-
erestimate the benefit of interventions on disabled and
hronically ill populations with a low baseline quality of life is
mong the criticisms. QALYs have become the standard mea-
urement of effectiveness in cost-effectiveness research, how-
ver, and for good reason: it is a single measurement that
ombines both survival and health utility. Additionally, be-
ause QALYs are calculated using global measures of health-
elated quality of life, the health benefits of wide variety of
ealth care programs can be compared without the limitations
hat might be posed by disease-specific measures of quality of
ife.
NTERPRETING THE RESULTS OF
OST-EFFECTIVENESS STUDIES
Incremental cost-effectiveness ratios (ICERS).
ost-effectiveness analyses are comparisons, so under-
tanding the most important comparative measure pro-
uced by these studies – the ICER – is critical to under-
tanding their results. Although the costs and effects of a
ingle health technology are notable by themselves, these
alues become more meaningful when they are considered
n relation to other health technologies. Thus, it is the
ncremental costs (the difference between the costs of two
ealth technologies) and the incremental effectiveness (the
ifference between the effectiveness of two health technol-
gies) that are the values of interest.
First, consider the costs and the effects of a health
echnology graphed on a two-dimensional plane with costs
epresented on the vertical axis and effectiveness repre-
ented on the horizontal axis. The reference health tech-
ology – by convention, the standard-of-care option or the
owest cost option – is represented by the origin of the axes.
second health technology can then displayed in relation
o the reference health technology by a position on the grid
hat is determined by its incremental cost on the vertical
xis and the incremental effectiveness on the horizontal
xis. Many health care technologies that produce more
ealth benefits are also more expensive, so this would be
eflected by a dot in the upper right quadrant of the grid
Fig). Alternatively, some health care technologies that
roduce more health benefits may actually do so at a lower
ost than the standard option. In cost-effectiveness terms,
his comparator health technology dominates the standard
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June 20121796 Barshes et alreference and would be represented by a position in the
lower right quadrant of the grid. Such options are impor-
tant to identify because they may produce overall cost-
savings while improving health. Other possibilities are that
comparator health technologies may also be less costly and
less effective than the reference (lower left quadrant) or
more costly and less effective than the reference (upper left
quadrant – the comparator is dominated by the reference
strategy).
The ICER is a ratio of the incremental costs to incre-
mental effectiveness. To demonstrate an example ICER
calculation, consider the hypothetical comparison of pri-
mary stenting of the superficial femoral artery for claudica-
tion using either bare metal stents or drug-eluting stents.
Suppose the strategy of using bare metal stents for a cohort
of 100 65-year-old claudicants cost $1.5 million (including
procedural costs, aspirin and/or Plavix and the cost of care
related to any subsequent interventions that were neces-
sary) and resulted in 800 QALYs, while drug-eluting stent
placement for the same cohort cost $2.5 million and re-
sulted in 850 QALYs. Compared with bare metal stents,
drug-eluting stents would therefore have an ICER of $1
million/50 QALYs, or $200,000/QALY.
Willingness-to-pay. So once ICERs are calculated,
how does one determine which health technology or man-
agement strategy is the most cost-effective? With limitless
monetary resources, there would be no need to limit
choices, and technologies that are more effective would be
adopted regardless of how high this cost may be. With finite
resources, however, finite limits on spending may need to
be adopted. In general, willingness-to-pay refers to the
Fig. A two-dimensional plane demonstrating the relationship of
incremental costs (vertical axis) and incremental effectiveness (hor-
izontal axis) for a reference and a comparator. See text for details.amount an individual, a group, or a society is willing to pay do produce a desirable health outcome or avoid an undesir-
ble health outcome.2 This willingness is obviously con-
trained by one’s ability to pay. In the context of health care
olicy, society (or alternatively, the policymakers who rep-
esent the society and the third parties that act as insurers
nd/or payers) may also draw a limit on the costs or
illingness-to-pay. The United Kingdom’s National Institute
or Health and Clinical Excellence has suggested that an
CER below £20,000 (approximately $33,000) per QALY
hould be considered cost-effective, but no strict national
hreshold exists.9 There is no explicit willingness-to-pay
hreshold for coverage in the United States. The range of
50,000 to $100,000 has been suggested, but this has been
riticized as being arbitrary.10,11
ODELING THE ACCUMULATION OF COSTS
ND EFFECTS
After obtaining estimates of the costs and utilities asso-
iated with the range of health states produced by a health
echnology, a cost-effectiveness analysis must combine the
otal costs and utilities for each health state after consider-
ng the frequency with which the health states occur and
he amount of time spent in each. To evaluate the manage-
ent of an asymptomatic 5 cm infrarenal abdominal
ortic aneurysm, for example, one might consider a hypo-
hetical cohort of 1000 patients undergoing endovascular
neurysm repair (EVAR). After EVAR, most patients will
emain asymptomatic and without further aneurysm
rowth until death from causes not related to the aneu-
ysm. Some proportion will have an endoleak that is asymp-
omatic but nonetheless requires treatment; this may not
ignificantly impact utility but would increase costs among
hese patients. A small proportion would experience early
erioperative mortality or have late rupture several years
fter EVAR. This subgroup would still accumulate the costs
ssociated with the EVAR procedure but would limit the
otal QALYs experienced by the group. Thus, the costs and
he QALYs differ among patients, but the model sums the
otal costs and QALYs based on frequency and duration of the
arious clinical states in the model.
The predominate means of totaling the time-dependent
ccumulation of costs and QALYs is through the use of a com-
uter model. The complexity of the computer model is
ictated by the clinical situation, but as the model complex-
ty increases, so does the difficulty of analysis and the risk of
rror. Nonetheless, these models are essential to contem-
orary cost-effectiveness analyses for several reasons. First,
fter the initial effort of creating the computer model is
ompleted, simulations can forecast the outcomes pro-
uced by health technologies that might otherwise have
equired years to determine in the context of a clinical trial.
t should be noted that the accuracy of any computer model
imulation is dependent on the structure of the model and
he accuracy of its parameters, and although simulations
ill never replace the need for high-quality observational
tudies or clinical trials, the forecasts produced by these
imulations can undoubtedly facilitate the planning and
esign as well as sharpen the focus of these studies.
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probabilistic, reflecting a degree of model or parameter
uncertainty that may come from several sources. In obser-
vational studies and clinical trials, the “true” value of a
parameter is only estimated, and differences in the param-
eter estimates obtained by various trials and studies is
attributed to heterogeneity of characteristics of the study
population and by fluctuations in results by random
chance. In addition, the “true” relationship between mul-
tiple variables is unknown; models can simulate the ob-
served relationships, but these represent approximations
and introduce some degree of uncertainty as well. These
sources of uncertainty are thus incorporated into a proba-
bilistic model by representing parameters not with a singu-
lar value but by a range of values. The range and type of
distribution for a parameter is chosen based on what is
known about the parameter and the degree of uncertainty
in its estimate. Therefore, in doing repeated simulations
(eg, 1000 repetitions to simulate the outcomes of 1000
hypothetical patients), the actual parameter value used
during a given repetition is a randomly chosen value that is
within the range of possible values for that parameter. With
repeated simulations, the costs and health effects that result
will therefore not be represented by a discrete point on a
two-dimensional plane but rather by a cluster of values.
Finally, because computer model simulations are repro-
ducible, a parameter or multiple parameters can be pur-
posefully and incrementally changed over a predetermined
range to help understand the impact of these changes on
the ultimate costs and effectiveness. This is referred to as a
deterministic sensitivity analysis. In addition to understand-
ing the impact of parameter changes, important thresholds
can be identified. In the previously mentioned hypothetical
EVAR model, for example, researchers can simulate the
impact of reducing the incidence of endoleak on the ICER
of EVAR or can estimate the “break-even” value at which
EVAR becomes more cost-effective than open surgical
repair.
COST-EFFECTIVENESS ANALYSIS IN
VASCULAR SURGERY
The care of patients presenting with critical limb isch-
emia of the lower extremities is often quite challenging.
Despite multiple costly and laborious interventions over an
extended period of time, limb salvage efforts may still fail,
resulting in limb loss. Primary amputation, in contrast, has
been suggested by some – even recently by vascular sur-
geons – to be a reasonable alternative.12-14 Numerous
studies published in the U.S. and abroad between 1983 and
1996 examined the costs and results of bypass and major
amputation but were limited by poor methodology (in-
cluding the use of charges rather than costs and no attempts
to account for indirect costs).15-22 A simple model pub-
lished by Brothers and colleagues found that bypass dom-
inated primary amputation and expectant management of
patients with critical limb ischemia but used an institutional
perspective and cost data that were estimated from hospital
charges.23 Hunink, along with a multi-institutional, multi- hisciplinary group of collaborators, used a lifelong time
orizon and hospital cost data from a separate background
tudy24 and long-term outpatient care costs to compare the
ost-effectiveness of bypass surgery to angioplasty. Bypass
urgery with vein conduit dominated angioplasty for pa-
ients with critical limb ischemia and femoropopliteal artery
cclusion. Although the methodology was of excellent
uality, the model is based on clinical and cost data that are
ow more than 15 years old. This study has other limits,
ncluding the fact that no more than two total interventions
ere allowed over the lifetime of the patient, that observa-
ion/local wound care only and primary amputation were
ot evaluated, and that the costs of postintervention wound
ealing were not included. Additionally, the model was
atency-oriented and did not include patient-oriented out-
omes such as ambulatory function or discharge disposi-
ion.25
The cost-effectiveness of the management of claudica-
ion has also been examined by Spronk and colleagues in
he context of a small clinical trial. This trial compared the
utcomes of percutaneous endovascular intervention to an
xercise regimen for patients with iliac and/or femoral
rtery stenosis. The clinical effectiveness as measured in
ALYs (albeit limited to 1 year after intervention) was
quivalent between the two groups, and the costs (as
easured from the societal perspective) were higher for the
ndovascular intervention group. The ICER for endovas-
ular therapy for claudication based on the data from this
rial was €231,800/QALY (2009 USD equivalent of ap-
roximately $313,000).26 Conclusions from this clinical
rial may be limited by the small size of the study group and
he limited length of follow-up, but nonetheless, it provides
ne of the only cost-effectiveness analyses in the treatment
f claudication.
Carotid endarterectomy has been well-studied from the
conomic perspective. For symptomatic patients, carotid
ndarterectomy appears to have an acceptably low
CER27,28 and may even be cost saving (ie, dominate) in
omparison to medical therapy.29 Estimates of the ICER
or carotid endarterectomy in the setting of asymptomatic
arotid stenosis vary depending on initial conditions such as
atient age, the perioperative mortality rate, and the cost of
he procedure.27,30,31 Carotid endarterectomy dominates
arotid angioplasty and stenting (ie, is both more effective
nd less costly) in three of the four studies that have compared
hese treatment strategies.32-35 The noninvasive screening of
symptomatic populations for carotid disease can be cost-
ffective,36,37 but routine surveillance for restenosis after
arotid endarterectomy does not appear to be.38
EVAR appears to dominate (ie, have lower cost and
ore QALYs than) open surgical repair for ruptured aneu-
ysms.39 For the elective repair of nonruptured aneurysms,
owever, the ICER of EVAR compared with open surgical
epair seems unfavorable ($268,337/QALY).40 The obser-
ation of small (5.5 cm) infrarenal abdominal aortic an-
urysms appears to be more cost-effective than repair for a
ypothetical 68-year-old patient, but the appeal of EVAR
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postoperative mortality is kept very low.41
Two studies have found that the ICER for an arterio-
venous fistula compared with an arteriovenous graft ranges
from $446 to $9389. This suggests that fistulas were clin-
ically preferable and cost-effective but that graft placement
would be a cost-effective option for those at risk for matu-
rational failure.42,43 Another model has suggested that
early referral of predialysis patients with chronic kidney
disease for dialysis access creation is cost-effective and
should be encouraged.44 Overall, the literature on the
cost-effectiveness of dialysis access procedures is sparse, and
more studies are needed.
POSSIBLE CLINICAL AND POLICY
IMPLICATIONS OF COST-EFFECTIVENESS
RESEARCH
As mentioned above, providers and administrators may
increasingly be asked to justify the existence of health care
programs and management choices in economic terms as
payers increasingly demand “value.” This demand may be
exhibited through local and national coverage decisions45
or through the actions of third-party watchdog groups such
as the Leapfrog Group or the Pacific Business Group on
Health.46 The U.S. Congressional Budget Office white
paper on comparative effectiveness research does include
some discussion of cost-effectiveness,47 but so far, there has
been little governmental funding for cost-effectiveness
analyses.48,49 The Centers for Medicare and Medicaid have
Table. Important concepts regarding cost-effectiveness
analyses
● Consumers and payers of U.S. health care are increasingly
demanding “value,” and providers may increasingly be asked
to demonstrate the value of the health care interventions they
provide. Cost-effectiveness analyses can be an important tool in
demonstrating value.
● The ICER, a ratio of the incremental costs to incremental
effectiveness of two health technologies, is the useful
measurement in cost-effectiveness analyses.
● Cost-effectiveness analyses are always comparative: for
example, the cost-effectiveness of femoropopliteal bypass for
claudication can be assessed fully only through a comparison
with medical management or some other management option.
● Cost-effectiveness analyses are always contextual: for example,
the ICER for EVAR compared with open surgical repair may
be quite different for elective repairs than for ruptured
aneurysms.
● The costs included in the study should include the costs to all
payers (ie, societal perspective) and cover a long time period
(ideally, a lifetime time horizon).
● Some degree of uncertainty and variability is inherent to
modeling, clinical research, and clinical practice. This
uncertainty and variability should be incorporated into
simulation models through probabilistic sensitivity analyses.
● Cost-effectiveness studies may serve as an important tool in
optimizing health care value but should not by themselves
guide treatment on an individual-patient basis.
EVAR,Endovascular aneurysm repair; ICER, incremental cost-effectiveness
ratios.avoided explicit limitations on treatment options, and the Onited States public may find unpalatable the degree to
hich coverage decisions have been limited by economic
onsiderations in the Oregon Health Plan or by the United
ingdom’s National Institute for Health and Clinical Ex-
ellence.50,51 Yet some compromise is needed, and it seems
ikely that some form of cost containment will occur.52
It is in the interest of vascular surgeons to be involved in
ost-effectiveness research. The foremost reason is to opti-
ize the value of the care provided. Vascular surgeons have
xcelled at maximizing clinical effectiveness in the manage-
ent of peripheral vascular disease. In the current eco-
omic climate, it would be irresponsible to not also con-
ider costs and cost-effectiveness. Indeed, costs may
ncrease to the point of jeopardizing the viability of a health
are institution or network and therefore jeopardize the
ission of providing health care. Analogous to paying off
ebt, minimizing inefficient or wasteful spending allows
esources to be redirected toward more cost-effective forms
f health care or toward investments such as research. In
ddition to optimizing value, researchers should participate
n cost-effectiveness research to aid in the construction of
odels that simulate vascular disease: no other clinician or
esearcher will understand the natural history and treat-
ent outcomes of vascular disease like vascular surgeons,
nd constructing such models helps identify areas of uncer-
ainty that merit further investigation, clarify the relation-
hip between important variables, and identify cost-
rivers that can be managed and used to improve the
ost-effectiveness of health care technologies.
ONCLUSIONS
The rate of growth of health care costs in the United
tates is simply unsustainable, and well-informed but diffi-
ult decisions will need to be made to limit or decrease
ealth care costs without sacrificing quality or outcomes.
ost-effectiveness research is an important tool that can
elp inform such decisions. As they have with the quality
nd safety initiatives, vascular surgeons should also cham-
ion the movement for providing cost-effective health care.
his can be done by recognizing the importance of cost-
ffectiveness or value in health care, understanding some of
he fundamental concepts (Table), participating in research
nd/or organized efforts to minimize costs and maximize
ealth benefits, and including discussion of costs and rela-
ive effectiveness in their conversations with patients.
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